J pineal Res Мелатонин как иммунорегулирующий агент
Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation
жүктеу/скачать 1.4 Mb.
|
- Бұл бет үшін навигация:
- AREAS COVERED
- EXPERT OPINION
- Melatonin and metformin inhibit skin carcinogenesis and lipid peroxidation induced by benz(a)pyrene in female mice.
- A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers.
Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation.Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Reiter RJ. INTRODUCTION:The possible oncostatic properties of melatonin on different types of neoplasias have been studied especially in hormone-dependent adenocarcinomas. Despite the promising results of these experimental investigations, the use of melatonin in breast cancer treatment in humans is still uncommon. AREAS COVERED:This article reviews the usefulness of this indoleamine for specific aspects of breast cancer management, particularly in reference to melatonin's antiestrogenic and antioxidant properties: i) treatments oriented to breast cancer prevention, especially when the risk factors are obesity, steroid hormone treatment or chronodisruption by exposure to light at night (LAN); ii) treatment of the side effects associated with chemo- or radiotherapy. EXPERT OPINION:The clinical utility of melatonin depends on the appropriate identification of its actions. Because of its SERM (selective estrogen receptor modulators) and SEEM (selective estrogen enzyme modulators) properties, and its virtual absence of contraindications, melatonin could be an excellent adjuvant with the drugs currently used for breast cancer prevention (antiestrogens and antiaromatases). The antioxidant actions also make melatonin a suitable treatment to reduce oxidative stress associated with chemotherapy, especially with anthracyclines, and radiotherapy. Мелатонин использует в онкологии : рак молочной профилактики рака и снижение побочных эффектов химиотерапии и радиации . Санчес - Barcelo Е.Ю., Mediavilla доктор медицинских наук, Алонсо- Гонсалес С , Райтер RJ . ВВЕДЕНИЕ : Возможные oncostatic свойства мелатонина на различных типах неоплазий были изучены особенно в гормонозависимых аденокарциномы . Несмотря на многообещающие результаты этих экспериментальных исследований , использование мелатонина в лечении рака молочной железы у человека по-прежнему редкость . Зоны покрытия: В этой статье рассматриваются полезность этого indoleamine для конкретных аспектов управления рака молочной железы , особенно в отношении антиэстрогенных и антиоксидантными свойствами мелатонина : Я ) лечения , ориентированных на профилактику рака молочной железы , особенно когда факторы риска являются ожирение , прием глюкокортикоидов гормон или chronodisruption воздействием на свет в ночное время (LAN) ; II) лечение побочных эффектов, связанных с химио- или лучевой терапии . Мнение эксперта: Клиническая полезность мелатонина зависит от соответствующей идентификации своих действий. Из-за своей SERM ( модуляторов рецепторов эстрогена селективный ) и, кажется (селективный фермент эстрогена модуляторы ) свойства и его практическое отсутствие противопоказаний , мелатонин может быть отличным адъювантной с наркотиками в настоящее время используются для профилактики рака молочной железы ( антиэстрогены и antiaromatases ). Антиоксидантные действия также сделать мелатонина подходящее лечение для снижения окислительного стресса , связанного с химиотерапией , особенно с антрациклинов , и лучевой терапии . Bull Exp Biol Med. 2011 Jul;151(3):363-5. Melatonin and metformin inhibit skin carcinogenesis and lipid peroxidation induced by benz(a)pyrene in female mice.[Article in English, Russian] Man'cheva TA, Demidov DV, Plotnikova NA, Kharitonova TV, Pashkevich IV, Anisimov VN. Outbred female SHR mice (n=200) were divided at random into 4 groups, 50 per group. Benz(a)pyrene solution in acetone was applied onto a skin site on the back during 26 weeks. In parallel, the animals received melatonin, metformin, or both. Melatonin, metformin, and their combination promoted significant reduction of the number and size of skin tumors. In mice receiving no therapy, benz(a)pyrene applications increased the concentrations of malonic dialdehyde in the serum and skin tumor tissue in comparison with the concentrations in the sera and skin of intact mice. Melatonin, metformin, and their combination normalized LPO level. Мелатонин и метформин ингибирует канцерогенез кожи и перекисное окисление липидов, индуцированного бенз (а) пирена в самок мышей.
We examined compliance with and the effects of melatonin supplementation on breast cancer biomarkers (estradiol, insulin-like growth factor I (IGF-1), insulin-like growth factor-binding protein 3 (IGFBP-3), and the IGF-1/IGFBP-3 ratio) in postmenopausal breast cancer survivors. In a double-blind, placebo-controlled study, postmenopausal women with a prior history of stages 0-III breast cancer who had completed active cancer treatment (including hormonal therapy) were randomly assigned to either 3 mg oral melatonin (n = 48) or placebo daily for 4 months. Plasma samples were collected at baseline and after the completion of the intervention. The primary endpoints were compliance and change in estradiol and IGF-1/IGFBP-3 levels. Ninety-five women were randomized (48 to melatonin and 47 to placebo). Eighty-six women (91%) completed the study and provided pre- and postintervention bloods. Melatonin was well tolerated without any grade 3/4 toxicity and compliance was high (89.5%). Overall, among postmenopausal women with a prior history of breast cancer, a 4-month course of 3 mg melatonin daily did not influence circulating estradiol, IGF-1, or IGFBP-3 levels. Compliance was comparable between the two groups. Short-term melatonin treatment did not influence the estradiol and IGF-1/IGBBP-3 levels. Effects of longer courses of melatonin among premenopausal women are unknown. Low baseline estradiol levels in our study population may have hindered the ability to detect any further estradiol-lowering effects of melatonin. Рандомизированное контролируемое исследование устных добавок мелатонина и рака молочной железы биомаркеров .
жүктеу/скачать 1.4 Mb. Достарыңызбен бөлісу:
|